PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed its first-in-man clinical study with the novel heparin antagonist drug PMX-60056. Continue reading ...
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment